Eli Lilly’s 2024 agreement with Peptron granted only non-exclusive research rights to the SmartDepot ultrasonic spray-dried PLGA microsphere platform for sustained peptide release, explicitly excluding commercial manufacturing or sales. Nearly two years later, no technology-transfer or licensing announcement has surfaced despite ongoing feasibility evaluations that were extended into 2026. Lilly’s June 2026 partnership with Camurus for the competing FluidCrystal platform targeting long-acting incretins has further signaled a shift away from Peptron’s technology. With the October 7 resolution date now roughly two months away and no credible catalysts reported, traders see limited scope for a binding commercial deal to materialize, producing the current 87.5% implied probability on “No.”
Experimental AI-generated summary referencing Polymarket data. This is not trading advice and plays no role in how this market resolves. · Updated13% chance
$11,264 Vol.
$11,264 Vol.
Oct 7, 2026
13% chance
$11,264 Vol.
$11,264 Vol.
Oct 7, 2026
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.Eli Lilly’s 2024 agreement with Peptron granted only non-exclusive research rights to the SmartDepot ultrasonic spray-dried PLGA microsphere platform for sustained peptide release, explicitly excluding commercial manufacturing or sales. Nearly two years later, no technology-transfer or licensing announcement has surfaced despite ongoing feasibility evaluations that were extended into 2026. Lilly’s June 2026 partnership with Camurus for the competing FluidCrystal platform targeting long-acting incretins has further signaled a shift away from Peptron’s technology. With the October 7 resolution date now roughly two months away and no credible catalysts reported, traders see limited scope for a binding commercial deal to materialize, producing the current 87.5% implied probability on “No.”
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Market Opened: May 5, 2026, 8:02 PM ET
Volume
$11,264End Date
Oct 7, 2026Market Opened
May 5, 2026, 8:02 PM ETResolver
0x65070BE91...This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.Eli Lilly’s 2024 agreement with Peptron granted only non-exclusive research rights to the SmartDepot ultrasonic spray-dried PLGA microsphere platform for sustained peptide release, explicitly excluding commercial manufacturing or sales. Nearly two years later, no technology-transfer or licensing announcement has surfaced despite ongoing feasibility evaluations that were extended into 2026. Lilly’s June 2026 partnership with Camurus for the competing FluidCrystal platform targeting long-acting incretins has further signaled a shift away from Peptron’s technology. With the October 7 resolution date now roughly two months away and no credible catalysts reported, traders see limited scope for a binding commercial deal to materialize, producing the current 87.5% implied probability on “No.”
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Volume
$11,264End Date
Oct 7, 2026Market Opened
May 5, 2026, 8:02 PM ETResolver
0x65070BE91...Eli Lilly’s 2024 agreement with Peptron granted only non-exclusive research rights to the SmartDepot ultrasonic spray-dried PLGA microsphere platform for sustained peptide release, explicitly excluding commercial manufacturing or sales. Nearly two years later, no technology-transfer or licensing announcement has surfaced despite ongoing feasibility evaluations that were extended into 2026. Lilly’s June 2026 partnership with Camurus for the competing FluidCrystal platform targeting long-acting incretins has further signaled a shift away from Peptron’s technology. With the October 7 resolution date now roughly two months away and no credible catalysts reported, traders see limited scope for a binding commercial deal to materialize, producing the current 87.5% implied probability on “No.”
Experimental AI-generated summary referencing Polymarket data. This is not trading advice and plays no role in how this market resolves. · Updated
Beware of external links.
Beware of external links.
Frequently Asked Questions